- Home
- REA vs GALT Comparison
REA vs GALT Comparison
Compare REA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REA | GALT |
|---|---|---|
| Founded | N/A | 2000 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.9M | 297.0M |
| IPO Year | 2026 | 2008 |
Fundamental Metrics
Financial Performance| Metric | REA | GALT |
|---|---|---|
| Price | $11.75 | $4.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 150.8K | ★ 1.1M |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.80 | $2.03 |
| 52 Week High | $17.84 | $7.13 |
Technical Indicators
Market Signals| Indicator | REA | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 16.75 | 68.65 |
| Support Level | N/A | $2.30 |
| Resistance Level | $16.18 | $5.26 |
| Average True Range (ATR) | 1.41 | 0.48 |
| MACD | -0.44 | 0.07 |
| Stochastic Oscillator | 6.16 | 74.05 |
Price Performance
Historical ComparisonAbout REA Rare Earths Americas Inc. Common Stock
Rare Earths Americas Inc is an exploration stage company focused on advancing projects related to rare earth minerals. Its activities include evaluating mineralization and assessing the characteristics and economic potential of its assets. Its portfolio includes the Shiloh Project in Georgia, United States; the Alpha Project in Bahia, Brazil; and the Constellation Project in Minas Gerais, Brazil. It also holds additional early-stage exploration projects, including the Homer Project in Goiás, Brazil, and the Liberty Peak Project in Georgia, United States. The company has two reportable segments due to their geographical location: United States Mining Operations and Brazil Mining Operations.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.